MONOVISC® High Molecular Weight Hyaluronan

Division: Sports Medicine
Category: Early Intervention

MONOVISC® High Molecular Weight Hyaluronan is a FDA approved treatment made from ultra-pure hyaluronan, a naturally occurring lubricant found in healthy knee joints. MONOVISC Hyaluronan is a NON-AVIAN sourced viscosupplement with lasting efficacy for up to 6 months with a single injection.
As OA of the knee progresses, prescription medications such as NSAIDs, COX-2 Inhibitors and intraarticular corticosteroid injections may be appropriate next course of therapy choices. Due to contraindications, co-morbidities or adverse events, COX-2 Inhibitors and/or NSAIDs may or may not be an appropriate choice.
These treatments may have provided relief to date but may no longer seem effective due to the disease state progression. A next-step consideration in the Continuum of Care for Knee Osteoarthritis is Hyaluronic Acid Injections, such as MONOVISC.

Indications for Use

MONOVISC is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g. acetaminophen. MONOVISC Hyaluronan may enhance the viscoelastic properties of synovial fluid to relieve pain and increase mobility

Features & Benefits

Features Benefits
High HA (Hyaluronic Acid) Concentration High concentration maximize the potential for impacting osteoarthritic cell function and restoring native HA production.
High Molecular Weight
Preclinical studies suggest that there is an optimal molecular weight (MW) of HA required to stimulate native HA production. 1
Optimal MW molecules bind strongly to synoviolcyte surface receptors, maximizing the stimulation of native HA.
Non-Avian ultra-pure HA MONOVISC is not derived from animal tissue. It has a very low residual protein content and can be prescribed to patients with known avian allergies.
Strong Safety Profile MONOVISC has a very low rate of adverse events. The results of the safety analysis indicate that MONOVISC is well tolerated with an adverse event profile similar to saline injection.2


1. Smith MM, Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int. 1987; 7(3):113-22
2. MONOVISC®(High Molecular Weight Hyaluronan) Full Prescribing Information. DePuy Mitek: Raynham, MA March 6, 2014
Important Safety Information
MONOVISC High Molecular Weight Hyaluronan is indicated in the treatment of pain in osteoarthritis (OA) of the
knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and to simple analgesics, e.g., acetaminophen. In clinical studies, the most commonly reported adverse events were arthralgia, joint swelling and injection site pain.
MONOVISC is contraindicated in patients with known hypersensitivity to hyaluronate formulations or known hypersensitivity (allergy) to gram positive bacterial proteins. MONOVISC should not be injected in patients with infections or skin diseases in the area of the injection site or joint. MONOVISC should not be administered to patients with known bleeding disorders.


Science of HA Brochure PDF


MONOVISC Package Insert PDF


ORTHOVISCLine Reimbursement Web Portal


All medical devices have associated risks. Please refer to the package insert and other labeling for a complete list of indications, contraindications, precautions and warnings. For further information on DePuy Synthes Products, please contact your local DePuy Synthes Representative.